

Technology appraisal (TA)	Date of TA Release	Adherence of local formulary to NICE	
		Included on the Trust Formulary for this indication Yes OR No	Reason provided if "No"
<b>2019-20</b>			
<a href="#">TA625 - Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal)</a>	04/03/2020	No	Terminated appraisal
<a href="#">TA624 - Peginterferon beta-1a for treating relapsing-remitting multiple sclerosis</a>	19/02/2020	Yes	
<a href="#">TA623 - Patiomer for treating hyperkalaemia</a>	13/02/2020	Yes	
<a href="#">TA622 - Sotagliflozin with insulin for treating type 1 diabetes</a>	12/02/2020	Awaiting availability	Not currently available commercially. To be added to the formulary when commercially available
<a href="#">TA621 - Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer</a>	22/01/2020	No	Not recommended
<a href="#">TA620 - Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer</a>	15/01/2020	No	Not applicable to CWFT - Not commissioned
<a href="#">TA619 - Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer</a>	15/01/2020	Yes	
<a href="#">TA618 - Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)</a>	15/01/2020	No	Terminated appraisal
<a href="#">TA617 - Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure</a>	08/01/2020	Yes	
<a href="#">TA616 - Cladribine for treating relapsing - remitting multiple sclerosis</a>	19/12/2019	Yes	
<a href="#">TA615 - Cannabidiol with clobazam for treating seizures associated with Lennox - Gastaut syndrome</a>	18/12/2019	No	Not applicable to CWFT - Not commissioned
<a href="#">TA614 - Cannabidiol with clobazam for treating seizures associated with Dravet syndrome</a>	18/12/2019	No	Not applicable to CWFT - Not commissioned
<a href="#">TA613 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy</a>	20/11/2019	No	Not recommended
<a href="#">TA612 - Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab</a>	20/11/2019	Yes	
<a href="#">TA611 - Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer</a>	13/11/2019	No	Not applicable to CWFT - Not commissioned
<a href="#">TA610 - Pentosan polysulfate sodium for treating bladder pain syndrome</a>	13/11/2019	Yes	
<a href="#">TA609 - Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (Terminated appraisal)</a>	30/10/2019	No	Terminated appraisal
<a href="#">TA608 - Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (Terminated appraisal)</a>	30/10/2019	No	Terminated appraisal
<a href="#">TA607 - Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease</a>	17/10/2019	Yes	
<a href="#">TA606 - Lanadelumab for preventing recurrent attacks of hereditary angioedema</a>	16/10/2019	No	Not applicable to CWFT - Not commissioned
<a href="#">TA605 - Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea</a>	09/10/2019	Yes	
<a href="#">TA604 - Idelalisib for treating refractory follicular lymphoma</a>	02/10/2019	No	Not recommended
<a href="#">TA603 - Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma</a>	25/09/2019	No	Terminated appraisal
<a href="#">TA602 - Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma</a>	25/09/2019	No	Terminated appraisal
<a href="#">TA601 - Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal)</a>	25/09/2019	No	Terminated appraisal
<a href="#">TA600 - Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer</a>	11/09/2019	Yes	
<a href="#">TA599 - Sodium zirconium cyclosilicate for treating hyperkalaemia</a>	04/09/2019	Yes	

<a href="#">TA598 - Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy</a>	28/08/2019	No	Not applicable to CWFT - Not commissioned
<a href="#">TA597 - Dapagliflozin with insulin for treating Type 1 Diabetes</a>	28/08/2019	Yes	
<a href="#">TA596 - Risankizumab for treating moderate to severe plaque psoriasis</a>	21/08/2019	Yes	
<a href="#">TA595 - Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer</a>	14/08/2019	Yes	
<a href="#">TA594 - Brentuximab vedotin for untreated advanced Hodgkin lymphoma (Terminated Appraisal)</a>	14/08/2019	No	Terminated appraisal
<a href="#">TA593 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer</a>	14/08/2019	Yes	
<a href="#">TA592 - Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma</a>	07/08/2019	Yes	CWFT currently not commissioned. To challenge this decision with NHS England.
<a href="#">TA591 - Letermovir for preventing cytomegalovirus disease after a stem cell transplant</a>	31/07/2019	No	Not applicable to CWFT - Not commissioned
<a href="#">TA590 - Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis</a>	31/07/2019	Yes	
<a href="#">TA589 - Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity</a>	24/07/2019	No	Not applicable to CWFT - Not commissioned
<a href="#">TA588 - Nusinersen for treating spinal muscular atrophy</a>	24/07/2019	No	Not applicable to CWFT - Not commissioned
<a href="#">TA587 - Lenalidomide plus dexamethasone for previously untreated multiple myeloma</a>	26/06/2019	Yes	
<a href="#">TA586 - Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib</a>	26/06/2019	Yes	
<a href="#">TA585 - Ocrelizumab for treating primary progressive multiple sclerosis</a>	12/06/2019	Yes	
<a href="#">TA584 - Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer</a>	05/06/2019	Yes	
<a href="#">TA583 - Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes</a>	05/06/2019	Yes	
<a href="#">TA582 - Cabozantinib for previously treated advanced hepatocellular carcinoma</a>	24/05/2019	No	Terminated appraisal
<a href="#">TA581 - Nivolumab with ipilimumab for untreated advanced renal cell carcinoma</a>	15/05/2019	Yes	
<a href="#">TA580 - Enzalutamide for hormone-relapsed non-metastatic prostate cancer</a>	15/05/2019	No	Not recommended
<a href="#">TA579 - Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy</a>	08/05/2019	Yes	
<a href="#">TA578 - Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation</a>	01/05/2019	Yes	
<a href="#">TA577 - Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma</a>	24/04/2019	Yes	
<a href="#">TA576 - Bosutinib for untreated chronic myeloid leukaemia (Terminated appraisal)</a>	17/04/2019	No	Terminated appraisal
<a href="#">TA575 - Tildrakizumab for treating moderate to severe plaque psoriasis</a>	17/04/2019	Yes	
<a href="#">TA574 - Certolizumab pegol for treating moderate to severe plaque psoriasis</a>	17/04/2019	Yes	
<a href="#">TA573 - Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma</a>	10/04/2019	Yes	